Trial Profile
THE EFFECT OF EFAVIRENZ AND RITONAVIR-BOOSTED DARUNAVIR ON THE PHARMACOKINETICS OF THE HMG CoA REDUCTASE INHIBITOR PITAVASTATIN
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Pitavastatin (Primary) ; Darunavir; Efavirenz; Ritonavir
- Indications Dyslipidaemias; HIV infections; Hypercholesterolaemia; Hyperlipidaemia
- Focus Pharmacokinetics
- 22 Jul 2020 Status changed from active, no longer recruiting to completed.
- 09 Oct 2012 New trial record